Get the Daily Brief
Latest Biotech News
Myriad Genetics and Sophia Genetics Collaborate on Global Cancer Liquid Biopsy Companion Diagnostic
Myriad Genetics and Sophia Genetics have entered a strategic collaboration to develop and commercialize a cancer liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad’s...
MapLight Therapeutics Files IPO to Advance Neuropsychiatric Drug Pipeline
Biotechnology company MapLight Therapeutics has filed for an initial public offering on Nasdaq under the ticker 'MPLT,' positioning itself to raise capital to advance its drug development programs...
Capsida Bio Halts Gene Therapy Trial for Rare Neurological Disease After Patient Death
Capsida Bio has paused its SYNRGY trial evaluating CAP-002, an adeno-associated virus-based gene therapy for STXBP1 encephalopathy, following the death of the first treated pediatric patient. The...
Pfizer Closes $4.9B Metsera Deal to Reenter Obesity Market
Pfizer has acquired Metsera for $4.9 billion upfront with potential payments raising the deal to $7.3 billion, regaining a foothold in the competitive obesity drug space after recent internal...
FDA Clears Injectable Keytruda Qlex for Solid Tumors in One-Minute Dose
Merck's Keytruda Qlex, a subcutaneous formulation of its flagship cancer immunotherapy, has received FDA approval, offering a one-minute injection alternative to the traditional 30-minute...
Scholar Rock’s Spinal Muscular Atrophy Drug Faces FDA Rejection Over Manufacturing Issues
The FDA has issued a complete response letter rejecting Scholar Rock’s apitegromab, a treatment for spinal muscular atrophy (SMA), due to unresolved manufacturing quality problems at a contract...
Ionis Pharmaceuticals’ Antisense Drug Shows Promise in Rare Neurological Disease
Ionis Pharmaceuticals reported positive phase 3 trial results for zilganersen, an antisense oligonucleotide for Alexander disease, a rare neurogenetic disorder. The drug demonstrated significant...
New Diagnostic Advances Targeting Acute Leukemia and Cancer Imaging
OGT’s CytoCell KMT2A Breakapart FISH Probe Kit received FDA de novo authorization as a companion diagnostic to identify acute leukemia patients with KMT2A gene translocations eligible for...
Roche’s Oral SERD Wins Phase 3 Breast Cancer Trial, Eyes Market Approval
Roche announced a successful phase 3 trial for its oral selective estrogen receptor degrader (SERD) in a broad breast cancer patient population. The drug outperformed standard of care, marking a...
Emerging Cancer Therapeutics: MBX Biosciences Posts Positive Phase II Data
MBX Biosciences’ experimental once-weekly therapy canvuparatide achieved primary endpoints in a phase 2 study treating chronic hypoparathyroidism, a rare hormone disorder. While statistically...
AI and Base Editing Tools: Revvity and Profluent Partnership Advances Gene Therapy Precision
Revvity and Profluent have partnered to develop an advanced base editing toolkit combining Profluent’s AI-engineered enzymes with Revvity's Pin-Point platform. This collaboration enhances the...
Breakthrough in Small Molecule Drug Stabilizing Diverse GPCR Mutants
Researchers at the Centre for Genomic Regulation in Barcelona discovered that a single, already licensed small molecule can stabilize nearly all mutated forms of the vasopressin V2 receptor (V2R),...
National Institutes of Health Launches $50M Autism Data Science Initiative
The NIH has announced a $50 million research program aiming to elucidate genetic and environmental factors driving autism spectrum disorder. The Autism Data Science Initiative funds 13 projects...
Pfizer’s Metsera Acquisition Intensifies Obesity Drug Race
Pfizer has significantly bolstered its obesity and metabolic disease pipeline by agreeing to acquire Metsera for up to $7.3 billion, including contingent value rights based on clinical milestones....
Regulatory Milestones and Novel Approvals in Oncology and Rare Diseases
Recent regulatory decisions mark significant progress in oncology and rare disease treatments. The FDA approved Stealth BioTherapeutics’ elamipretide as the first therapy for Barth syndrome after...
AI and Machine Learning Transform Drug Development and Clinical Trials
Artificial intelligence is increasingly integrated into drug development and clinical trial optimization. Advarra launched an AI-driven platform, Study Design, that analyzes thousands of...
Innovations in Cancer Therapy and Molecular Imaging
Cutting-edge developments are advancing cancer treatment and diagnosis. A novel PET tracer targeting nectin-4 enables same-day imaging of aggressive triple-negative breast and urothelial cancers,...
Synthetic Biology and Gene Editing Advancements
Innovations in gene editing continue to expand functional capabilities. Korean researchers developed a dual-mode CRISPR system capable of simultaneous gene activation and repression, surpassing...
Breakthroughs Linking Metabolism and Neuroinflammation
Emerging research elucidates metabolic pathways influencing neuroinflammatory conditions. A study published in Nature Metabolism uncovered cholesterol metabolism’s central role in sustaining...
AI and Machine Learning in Psychiatric and Neurological Disorders
Researchers are deploying AI to advance diagnostics in complex brain disorders. Johns Hopkins scientists developed machine learning classifiers with up to 95.8% accuracy to detect...